These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 25193617

  • 21. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
    Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S.
    Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
    [Abstract] [Full Text] [Related]

  • 22. Curcumin for maintenance of remission in ulcerative colitis.
    Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD008424. PubMed ID: 23076948
    [Abstract] [Full Text] [Related]

  • 23. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.
    Ito H, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T, Takano Y, Hibi T.
    Inflamm Bowel Dis; 2010 Sep 17; 16(9):1567-74. PubMed ID: 20049950
    [Abstract] [Full Text] [Related]

  • 24. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE.
    Aliment Pharmacol Ther; 2007 Jul 15; 26(2):205-15. PubMed ID: 17593066
    [Abstract] [Full Text] [Related]

  • 25. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
    Lichtenstein GR, Barrett AC, Bortey E, Paterson C, Forbes WP.
    Inflamm Bowel Dis; 2014 Aug 15; 20(8):1399-406. PubMed ID: 24874460
    [Abstract] [Full Text] [Related]

  • 26. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study.
    Moss AC, Chaudhary N, Tukey M, Junior J, Cury D, Falchuk KR, Cheifetz AS.
    J Crohns Colitis; 2010 Jun 15; 4(2):171-5. PubMed ID: 21122501
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
    Nagahori M, Kochi S, Hanai H, Yamamoto T, Nakamura S, Omuro S, Watanabe M, Hibi T, OPTIMUM Study Group.
    BMC Gastroenterol; 2017 Apr 04; 17(1):47. PubMed ID: 28390410
    [Abstract] [Full Text] [Related]

  • 30. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis.
    McCormack PL, Robinson DM, Perry CM.
    Drugs; 2007 Apr 04; 67(17):2635-42. PubMed ID: 18034594
    [Abstract] [Full Text] [Related]

  • 31. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.
    Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG.
    Gastroenterology; 2013 Jul 04; 145(1):149-157.e2. PubMed ID: 23528626
    [Abstract] [Full Text] [Related]

  • 32. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
    Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S.
    United European Gastroenterol J; 2019 Nov 04; 7(9):1164-1170. PubMed ID: 31700629
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.